: Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval

Madrigal Pharmaceuticals’ resmetirom is a leading treatment candidate for the advanced form of fatty liver disease.

Previous post Crypto: Crypto company Paxos confirms SEC notice of potential charges relating to BUSD stablecoin
Next post The Margin: Inflation can’t stop Cupid: Americans are spending almost $200 apiece on Valentine’s Day – and $26 billion overall